Results 161 to 170 of about 655,557 (182)

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. [PDF]

J Med Chem
Himmelbauer MK, Bajrami B, Basile R, Capacci A, Chen T, Choi CK, Gilfillan R, Gonzalez-Lopez de Turiso F, Gu C, Hoemberger M, Johnson DS, Jones JH, Kadakia E, Kirkland M, Lin EY, Liu Y, Ma B, Magee T, Mantena S, Marx IE, Metrick CM, Mingueneau M, Murugan P, Muste CA, Nadella P, Nevalainen M, Parker Harp CR, Pattaropong V, Pietrasiewicz A, Prince RJ, Purgett TJ, Santoro JC, Schulz J, Sciabola S, Tang H, Vandeveer HG, Wang T, Yousaf Z, Helal CJ, Hopkins BT.   +39 more
europepmc   +1 more source

Successful treatment of hemophagocytic intravascular large B-cell lymphoma with CNS involvement with BTK inhibitor combined with rituximab and high-dose methotrexate. [PDF]

Ther Adv Hematol
Shao F, Su W, Zhao X, He J, Wang X, Guo F, Xiao H.   +6 more
europepmc   +1 more source

Labeling of Bruton's Tyrosine Kinase (BTK) Inhibitor [¹¹C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET. [PDF]

Int J Mol Sci
Nag S, Datta P, Morén AF, Khani Y, Martarello L, Kaliszczak M, Halldin C.   +6 more
europepmc   +1 more source

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia [PDF]

New England Journal of Medicine, 2023
In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 ...
Chan Yoon Cheah, Francisco J Hernandez-Ilizaliturri, Amy Stark   +2 more
exaly   +5 more sources

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Molecular Therapy - Oncolytics, 2021
Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials ...
Yuqin Song, Xiaogan Wang
exaly   +2 more sources

BTK inhibitors: past, present, and future

Trends in Pharmacological Sciences
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by covalent BTK inhibitors that ...
Skye Montoya, Justin Taylor
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma

Future Oncology, 2022
Amy Stark, Toby A Eyre, Mitul Gandhi
exaly  

BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS

Drug Metabolism and Pharmacokinetics, 2022
Cathy Muste
exaly  

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

Journal of Allergy and Clinical Immunology, 2022
Pauline Walsh
exaly